Akero Therapeutics Crecimiento futuro

Future controles de criterios 0/6

Se prevé un crecimiento anual de los beneficios y los ingresos de Akero Therapeutics de 5.1% y 69.6% por año respectivamente. Se prevé que el BPA crezca en un 9.1% al año. Se espera que la rentabilidad financiera sea de -115.5% en 3 años.

Información clave

9.2%

Tasa de crecimiento de los beneficios

13.9%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Biotechs	24.8%
Tasa de crecimiento de los ingresos	77.0%
Rentabilidad financiera futura	-66.7%
Cobertura de analistas	Good
Última actualización	13 May 2024

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Akero Therapeutics (NASDAQ:AKRO) Is In A Good Position To Deliver On Growth Plans

Oct 01

Akero: Ticking All The Right Boxes In NASH

Sep 23

Akero Therapeutics (NASDAQ:AKRO) Is In A Good Position To Deliver On Growth Plans

Jun 10

Previsiones de crecimiento de beneficios e ingresos

NasdaqGS:AKRO - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2026	6	-281	-211	-241	4
12/31/2025	N/A	-270	-204	-253	6
12/31/2024	N/A	-234	-174	-174	6
3/31/2024	N/A	-179	-156	-156	N/A
12/31/2023	N/A	-152	-145	-145	N/A
9/30/2023	N/A	-120	-122	-122	N/A
6/30/2023	N/A	-116	-97	-97	N/A
3/31/2023	N/A	-112	-94	-94	N/A
12/31/2022	N/A	-112	-93	-93	N/A
9/30/2022	N/A	-121	-94	-94	N/A
6/30/2022	N/A	-110	-84	-84	N/A
3/31/2022	N/A	-112	-84	-84	N/A
12/31/2021	N/A	-101	-80	-80	N/A
9/30/2021	N/A	-98	-76	-76	N/A
6/30/2021	N/A	-95	-75	-75	N/A
3/31/2021	N/A	-82	-78	-78	N/A
12/31/2020	N/A	-79	-71	-71	N/A
9/30/2020	N/A	-65	-59	-59	N/A
6/30/2020	N/A	-59	-59	-59	N/A
3/31/2020	N/A	-50	-41	-41	N/A
12/31/2019	N/A	-44	-36	-36	N/A
9/30/2019	N/A	-90	-26	-26	N/A
6/30/2019	N/A	-86	-15	-15	N/A
3/31/2019	N/A	-87	-15	-10	N/A
12/31/2018	N/A	-82	-10	-5	N/A
9/30/2018	N/A	-22	-9	-4	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Se prevé que AKRO siga sin ser rentable en los próximos 3 años.

Beneficios vs. Mercado: Se prevé que AKRO siga sin ser rentable en los próximos 3 años.

Beneficios de alto crecimiento: Se prevé que AKRO siga sin ser rentable en los próximos 3 años.

Ingresos vs. Mercado: Se prevé que AKRO no tenga ingresos el año que viene.

Ingresos de alto crecimiento: Se prevé que AKRO no tenga ingresos el año que viene.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: AKRO se prevé que no sea rentable en 3 años.

Akero Therapeutics Crecimiento futuro

Future controles de criterios 0/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Price target increased by 13% to US$48.38

Price target decreased by 29% to US$48.44

Price target increased by 7.3% to US$67.75

Price target increased by 7.7% to US$64.75

Price target increased to US$52.00

Price target increased to US$48.33

Recent updates

Insufficient new directors

Akero Therapeutics Appoints Scott Gangloff as Chief Technology Officer

Robbins Geller Rudman & Dowd LLP Files Class Action Lawsuit Against Akero Therapeutics, Inc

Co-Founder notifies of intention to sell stock

Akero Therapeutics' EFX Data Warrants Caution

Akero Therapeutics, Inc. Announces Publication of Phase 2b SYMMETRY Cohort D Study in Clinical Gastroenterology and Hepatology

Akero Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $319 million.

President notifies of intention to sell stock

Akero Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $319 million.

Akero Therapeutics Reports Statistically Significant Histological Improvements at Week 96 in Phase 2b HARMONY Study

Price target increased by 13% to US$48.38

Akero: Phase 2b NASH Data Bodes Well For Phase 3 SYNCHRONY Program

New major risk - Revenue and earnings growth

New minor risk - Share price stability

Akero Therapeutics, Inc. Announces First Patients Dosed in Efruxifermin Phase 3 Synchrony Program

President exercised options and sold US$368k worth of stock

Co-Founder recently sold US$440k worth of stock

Price target decreased by 29% to US$48.44

Akero Therapeutics, Inc. Reports Encouraging 36-Week Analysis of 96-Week Phase 2b SYMMETRY Study, with a Trend on Fibrosis Improvement and Statistically Significant Results for NASH Resolution, Markers of Liver Injury and Fibrosis, Insulin Sensitization and Lipoproteins

New major risk - Share price stability

Akero Therapeutics, Inc. to Present Results from Phase 2B Symmetry Study Investigating Efruxifermin in Patients with Compensated Cirrhosis Due to NASH

Akero Therapeutics, Inc. Announces Publication of the Harmony Phase 2B Trial Results in the Lancet Gastroenterology & Hepatology

President notifies of intention to sell stock

Price target increased by 7.3% to US$67.75

Price target increased by 7.7% to US$64.75

Insider notifies of intention to sell stock

Akero Therapeutics, Inc. to Report Results of Phase 2b SYMMETRY Study in October 2023

President exercised options and sold US$920k worth of stock

Co-Founder & Chief Scientific Officer notifies of intention to sell stock

Akero Therapeutics, Inc.(NasdaqGS:AKRO) dropped from Russell Small Cap Comp Value Index

Co-Founder & Chief Scientific Officer recently sold US$2.1m worth of stock

Co-Founder & Chief Scientific Officer notifies of intention to sell stock

President exercised options and sold US$1.1m worth of stock

Akero Therapeutics, Inc. Releases Topline Data from an Expansion Cohort of the Phase 2B SYMMETRY Study

President exercised options and sold US$1.1m worth of stock

President notifies of intention to sell stock

President exercised options and sold US$1.2m worth of stock

President exercised options and sold US$1.2m worth of stock

Insider notifies of intention to sell stock

Akero Therapeutics, Inc. Announces the Appointment of Patrick Lamy as Senior Vice President, Commercial Strategy

Co-Founder exercised options and sold US$544k worth of stock

Price target increased to US$52.00

Akero Therapeutics, Inc. Completes Enrollment of Phase 2B SYMMETRY Study

President exercised options and sold US$455k worth of stock

Independent Director recently sold US$1.1m worth of stock

President exercised options and sold US$428k worth of stock

Independent Director recently sold US$12m worth of stock

Price target increased to US$48.33

Co-Founder & Chief Scientific Officer exercised options and sold US$299k worth of stock

Akero Therapeutics announces closing of upsized public offering

President notifies of intention to sell stock

Akero Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $200.000008 million.

Akero Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $200.000008 million.

Akero Therapeutics, Inc. Releases Topline Data from HARMONY

Akero adds over 100% rallying peers after NASH success

Akero Therapeutics, Inc. Announces Results from Cohort C of its Phase 2a BALANCED trial in non-alcoholic steatohepatitis

Price target decreased to US$41.67

Akero Therapeutics Presents Analysis at the 2022 International Liver Congress Showing that Efruxifermin Improved Histopathology and Markers of Liver Injury Across PNPLA3 Genotypes in Patients with NASH Fibrosis

Akero Therapeutics, Inc. announced that it expects to receive $100 million in funding from Hercules Capital, Inc.

High number of new directors

We're Not Very Worried About Akero Therapeutics' (NASDAQ:AKRO) Cash Burn Rate

High number of new directors

President exercised options and sold US$170k worth of stock

Akero Therapeutics Completes Enrollment of Phase 2b HARMONY Study in Pre-Cirrhotic NASH Patients

President exercised options and sold US$169k worth of stock

Executive VP exercised options and sold US$146k worth of stock

We Think Akero Therapeutics (NASDAQ:AKRO) Can Afford To Drive Business Growth

President exercised options and sold US$189k worth of stock

Executive VP exercised options and sold US$99k worth of stock